We are live on ! Find out more
SFM

Sphera Funds Management Portfolio holdings

AUM $767M
1-Year Est. Return 119.71%
This Fund
S&P 500
This Quarter Est. Return
+17.33%
1 Year Est. Return
+119.71%
3 Year Est. Return
+244.81%
5 Year Est. Return
+382.5%
10 Year Est. Return
+2,655.81%
AUM
$961M
AUM Growth
+$374M
Cap. Flow
+$41.2M
Cap. Flow %
4.29%
Top 10 Hldgs %
44.93%
Holding
194
New
69
Increased
29
Reduced
39
Closed
48

Top Buys

Rank Stock Value
1
ABBV icon
AbbVie
ABBV
+$24.6M
2
AGN
Allergan plc
AGN
+$24.2M
3
MRK icon
Merck
MRK
+$22.3M
4
AMGN icon
Amgen
AMGN
+$17.6M
5
ENDP
Endo International plc
ENDP
+$17.6M

Top Sells

Rank Stock Value
1
NVS icon
Novartis
NVS
+$33.6M
2
SHPG
Shire pic
SHPG
+$20.7M
3
SLXP
SALIX PHARMACEUTICALS LTD DEL
SLXP
+$18.2M
4
BIIB icon
Biogen
BIIB
+$11.8M
5
ISRL
Isramco Inc
ISRL
+$11.1M

Sector Composition

Rank Sector Weight
1 Healthcare 59.2%
2 Miscellaneous 33.43%
3 Technology 2.61%
4 Industrials 1.8%
5 Consumer Discretionary 1.51%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BRCM
51
DELISTED
BROADCOM CORP CL-A
BRCM
$4.36M 0.45%
100,800
+12,000
+14% +$523K
CVS icon
52
CVS Health
CVS
$115B
$4.36M 0.45%
42,260
+5,650
+15% +$572K
XLV icon
53
State Street Health Care Select Sector SPDR ETF
XLV
$43.8B
$4.34M 0.45%
59,853
+11,000
+23% +$785K
ALXN
54
DELISTED
Alexion Pharmaceuticals
ALXN
$4.33M 0.45%
+25,000
New +$4.53M
ALDR
55
DELISTED
Alder Biopharmaceuticals
ALDR
$4.33M 0.45%
150,000
+50,000
+50% +$1.37M
PTCT icon
56
PTC Therapeutics
PTCT
$5.68B
$4.26M 0.44%
70,000
-40,000
-36% -$2.44M
ICPT
57
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
$4.23M 0.44%
15,000
+5,000
+50% +$1.08M
BIIB icon
58
Biogen
BIIB
$32.4B
$4.22M 0.44%
10,000
-30,000
-75% -$11.8M
SBUX icon
59
Starbucks
SBUX
$110B
$4.13M 0.43%
174,616
+126,616
+264% +$5.69M
AOS icon
60
A.O. Smith
AOS
$7.74B
$4.04M 0.42%
+123,200
New +$3.75M
KITE
61
DELISTED
Kite Pharma, Inc.
KITE
$3.81M 0.4%
65,970
-45,000
-41% -$3.02M
PTLA
62
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
$3.8M 0.4%
100,023
+30,023
+43% +$1.03M
ARIA
63
DELISTED
Ariad Pharmaceuticals Inc
ARIA
$3.67M 0.38%
+445,000
New +$3.29M
PTCT icon
64
CALL
PTC Therapeutics
PTCT
$5.68B
$3.65M 0.38%
+600
New +$36.6K
FEZ icon
65
State Street SPDR EURO STOXX 50 ETF
FEZ
$4.36B
$3.65M 0.38%
+94,000
New +$3.55M
ITCI
66
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$3.58M 0.37%
+150,000
New +$3.36M
PRTA icon
67
Prothena Corp
PRTA
$434M
$3.36M 0.35%
88,133
+25,501
+41% +$654K
DYAX
68
PUT
DELISTED
DYAX CORPORATION
DYAX
$3.35M 0.35%
+2,000
New +$31.1K
ESPR
69
DELISTED
Esperion Therapeutics
ESPR
$3.33M 0.35%
+36,000
New +$2.32M
TJX icon
70
TJX Companies
TJX
$139B
$3.31M 0.35%
94,660
-40,600
-30% -$1.38M
SAGE
71
DELISTED
Sage Therapeutics
SAGE
$3.3M 0.34%
65,724
-14,000
-18% -$602K
PBYI icon
72
Puma Biotechnology
PBYI
$491M
$3.26M 0.34%
13,796
-6,500
-32% -$1.39M
EWG icon
73
iShares MSCI Germany ETF
EWG
$1.69B
$3.22M 0.34%
+108,000
New +$3.1M
GWPH
74
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
$3.19M 0.33%
+35,000
New +$2.84M
VIRX
75
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$3.19M 0.33%
+6,190
New +$3.12M
1 2
3
4 5

Similar funds

ISWM
Independent Solutions Wealth Management Williamsville, New York $766M AUM 31.53% 1-Year Est. Return
ACP
Albar Capital Partners London, United Kingdom $767M AUM 61.96% 1-Year Est. Return
NIM
Nexus Investment Management Toronto, Ontario, Canada $767M AUM 30.97% 1-Year Est. Return
ACM
Arvin Capital Management Austin, Texas $766M AUM 36.51% 1-Year Est. Return
CBT
Crews Bank & Trust Wauchula, Florida $766M AUM 19.5% 1-Year Est. Return
SPIA
Strategic Point Investment Advisors Providence, Rhode Island $767M AUM 17.58% 1-Year Est. Return
CNB
Camden National Bank Camden, Maine $767M AUM 14.32% 1-Year Est. Return
HI
Hendershot Investments Centreville, Virginia $766M AUM 10.81% 1-Year Est. Return

Sphera Funds Management's Q1 2015 Portfolio in Review

As of Q1 2015, Sphera Funds Management held 194 positions worth $961M, up 64% from $587M the previous quarter. Its ten largest holdings account for 45% of the portfolio.

Sphera Funds Management deployed $41.2M of net new capital in Q1 2015, opening 69 new positions and adding to 29 existing holdings. Its largest new stake was AbbVie: 407,000 shares worth $23.8M.

By sector, the portfolio is most concentrated in Healthcare at 59% of assets, down from 69% a quarter earlier, followed by Miscellaneous and Technology.

On the sell side, the largest reduction was Novartis, an estimated $33.6M trimmed.

  • Sphera Funds Management's largest Q1 2015 buy was AbbVie: 407,000 shares worth $23.8M.
  • Sphera Funds Management added most to Allergan plc in Q1 2015, an estimated $24.2M increase.
  • Sphera Funds Management's biggest Q1 2015 reduction was Novartis, cutting an estimated $33.6M.
  • Sphera Funds Management fully exited SALIX PHARMACEUTICALS LTD DEL in Q1 2015, selling an estimated $18.2M.
  • Sphera Funds Management's ten largest holdings make up 45% of its $961M portfolio in Q1 2015.
  • Sphera Funds Management opened 69 new positions and closed 48 in Q1 2015.
  • Sphera Funds Management's portfolio value rose 64% quarter-over-quarter to $961M.

Based on Sphera Funds Management's 13F filing for Q1 2015, filed 11 May 2015.